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Abstract 
A 61-year-old woman who underwent HeartMate II left ventricular assist device 
placement for non-ischemic cardiomyopathy developed elevated lactate 
dehydrogenase within two weeks after implantation. After eight months of 
observation and several hospital admissions during which there was no 
evidence of pump thrombosis, she presented with clinically manifest 
hemolysis. During pump exchange there was notable pannus formation on the 
inflow cannula of the left ventricular assist device. The pannus around the 
inflow likely existed for several months, limiting the flow and creating a low-
grade hemolysis and this low flow state stimulated thrombus formation 
triggering gross hemolysis. Thoratec analysis of the pump confirmed that the 
clot was present for about 5 days. Lactate dehydrogenase normalized after 
pump exchange.  
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Introduction 
Left ventricular assist devices (LVAD) have become an integral tool in the 
treatment of patients with refractory heart failure [1] as they decrease morbidity, 
prolong survival [2] and improve the quality of life [3]. According to the 
INTERMACS registry, more than 10000 LVADs have been implanted since 2006 
in yearly increasing increments with nearly 2500 LVADs implanted in 2013 [4].  
Recently, several high volume LVAD centers reported markedly increased 
incidence of pump thrombosis compared with the data from clinical trials [5]. This 
complication typically presents as hemolysis, and elevated lactate 
dehydrogenase (LDH) is the most reliable early sign [6]. Therefore, many centers 
routinely follow LDH level after LVAD implantation and advise immediate 
hospitalization based on elevated LDH alone. Other causes of LVAD obstruction, 
resulting in elevated LDH, are less frequent.  There is scant data in the literature 
on hemolysis due to pannus formation. We describe a case of consistently 
elevated LDH for 8 months after LVAD implant due to pannus formation causing 
partial obstruction of the inflow cannula followed by gross hemolysis with onset of 
pump thrombosis. 
Case presentation 
A 61 year-old-woman with non-ischemic cardiomyopathy had recurrent hospital 
admissions due to decompensated heart failure and underwent HeartMate II 
LVAD placement. Preoperative laboratory workup showed no features of 
hypercoagulability. Heparin infusion was initiated on postoperative day 1 with a 
target partial thromboplastin time of 55- 65 seconds until an INR level of 2 was 
achieved. She was discharged on aspirin, persantine, and warfarin therapy. Her 
baseline LDH ranged between 400 and 500 IU/L. Within the first two weeks after 
LVAD implantation LDH started rising, never decreased to a level below 600 
IU/L, ranging between 652 to 2258 IU/L. Because of this, the goal for INR was 
increased to 2.5-3.5, and she stayed within the range. Although she felt 
somewhat better than before surgery, walking longer and further caused 
lightheadedness, and over the course of several months she had two falls. Her 
target INR was increased to 2.5-3.5. Two months after this adjustment, she was 
admitted with gastrointestinal bleeding, and her INR goal was shifted again to 
2.0-3.0. In addition we lowered the dose of aspirin from 325 mg/day to 81 mg/day 
and discontinued persantine. 
An echocardiogram showed 2D and color Doppler features consistent with 
normal appearance of the LVAD device. On ramp study, with the device speed 
changed from 8000 rpms to 11000 rpms, left ventricular end-diastolic dimension 
decreased from 5 cm to 4.4 cm, and aortic valve opening time decreased from 
230 ms to 100 ms, with both parameters consistent with normal pump function. 
We were unable to obtain good Doppler flow across the mitral valve in diastole to 
measure E wave deceleration time. Pump parameters were checked every two to 
three weeks with no evidence of major power spikes. A computed tomography 
angiogram (CTA) showed no evidence of thrombus formation in the inflow or 
outflow cannula. Eight months after device placement and continued LDH 
elevation, the patient presented with dark cola-colored urine and LDH was 3360 
IU/L. She was experiencing shortness of breath and fatigue not different from her 
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symptoms before LVAD placement. The HeartMate II impeller pump was 
removed and a HeartWare centrifugal pump was implanted. There was evidence 
of pannus formation on the inflow cannula of the HeartMate pump (figure 1).  
 
 
Figure 1. Intraoperative direct view illustrating pannus formation at LVAD inflow 
cannula 
 
The device was sent to Thoratec for analysis who confirmed that a thrombus 
aged about 5 days was present. The pannus around the inflow cannula likely 
existed for several months, limiting the flow and created low-grade hemolysis 
(evident as continued LDH elevation). This low flow state stimulated thrombus 
formation triggering gross hemolysis. Lactate dehydrogenase returned to normal 
level after LVAD exchange. Figure 2 illustrates the longitudinal LDH values from 
the onset of LVAD implantation till its replacement. 
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Figure 2. Longitudinal values of lactate dehydrogenase after HeartMate II 
placement from device implantation till explant  
Discussion 
A low level of hemolysis is common in all extracorporeal circuits with a rotatory 
pump. Clinically significant hemolysis is one of the feared complications that is 
increasingly recognized after LVAD support and is associated with increased 
mortality. Ravichandran et al. [7] compared patients with Heartmate II with and 
without hemolysis and found that survival in the hemolysis group was markedly 
decreased at one year (38.9% vs. 89.3% in those with and without hemolysis, 
respectively, p < 0.001). Hemolysis is suspected when a patient develops new 
onset anemia in absence of a bleeding source and manifest with dark cola-
colored urine, elevated plasma free hemoglobin (PFHb), hyperbilirubinemia with 
undetectable haptoglobin and elevated LDH [8]. Shah et al. found that an LDH > 
600 IU/L for HeartMate II is a superior marker of hemolysis [9] compared with a 
PFHb > 40 mg/dl which has been used to define significant hemolysis in the 
INTERMACS registry [10]. Other features of hemolysis –as a result of pump 
malfunction- include a new palpable pulse, the development of heart failure 
symptoms, increased pump power, new opening of the aortic valve and 
worsening of mitral regurgitation on echocardiography [11]. 
The most concerning cause of hemolysis in LVAD patients is pump thrombosis 
which should prompt pump replacement or cardiac transplantation to reduce 
mortality [5]. Other treatment options include thrombolytic therapy which has a 
54.3 % success rate and glycoprotein IIb/IIIa antagonist which has a 39.3 % 
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success rate compared with 75.5 % success rate with pump exchange [8]. In the 
study by Ravichandran et al., all patients with evidence of hemolysis had partial 
to complete pump thrombosis at explant and they concluded that hemolysis likely 
serves as a marker of pump thrombosis [7]. Other less common causes of 
hemolysis include cannulae/device malpositioning or migration and kinking or 
pannus formation on the inflow or outflow cannula. There is little data in the 
literature on hemolysis due to pannus formation on the inflow cannula of 
HeartMate II. Pannus is an avascular mass of fibrous tissue and its pathogenesis 
is not fully understood [12]. Comparison between pannus and thrombus 
formation was better studied with prosthetic heart valves. Unlike in thrombus 
formation, suboptimal anticoagulation did not appear to be a risk factor for 
pannus development; in addition, a longer period is required for pannus 
formation, usually 6 months or longer [13]. However, a shorter time interval for 
pannus formation has also been reported [14]. In the presented case, pannus 
formation likely occurred in the early postoperative period as evident by elevation 
of LDH within 2 weeks after LVAD implantation and was responsible for 
persistent LDH elevation for 8 months. The onset of clinically manifest hemolysis 
occurred with the development of LVAD thrombus due to the continued low flow 
state which prompted pump exchange. 
In the presented case, preoperative imaging failed to delineate a cause for the 
continued LDH elevation. The capacity of echocardiography to evaluate the 
inflow and outflow cannula is limited by acoustic window/shadowing and cannula 
artifact. Uriel et al. demonstrated that their “ramp” test protocol reliably detected 
LVAD thrombosis and malfunction through attenuated reduction in LV 
dimensions and increased power detected by the LVAD console with increasing 
LVAD pump speed [15]. Estep et al. showed that the best diagnostic parameters 
included changes in the LV end-diastolic diameter (<0.6 cm), aortic valve 
opening time (<80 msec), and deceleration time of mitral inflow (<70 msec) from 
lowest to highest pump speed [16]. Although CTA is an important tool to 
delineate the anatomy of the inflow cannula within the left ventricle, the 
extracardiac portion cannot be assessed with imaging and intraoperative 
inspection is needed. Moreover, it is unable to detect thrombus within the LVAD 
pump itself. Identifying the cause of hemolysis using echocardiography, CTA, or 
cardiac catheterization may not be definitive and occasionally intraoperative 
examination with extensive dissection to visualize the entire system is 
mandatory. Mechanical pump or inflow graft failure is therefore a diagnosis of 
exclusion and has been identified as the “black box” area that cannot be 
examined with preoperative imaging [17]. The presented case highlights one of 
the rare causes of chronic hemolysis after LVAD placement which is inflow 
cannula pannus formation. 
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